by Sarah Martin | August 25, 2015 | Health Risk Solutions, Pharmacy
Last week, a new drug called Addyi, manufactured by Sprout Pharmaceuticals, was approved by the Food and Drug Administration (FDA). The drug is intended for use by pre-menopausal women diagnosed with hypoactive sexual desire disorder (HSDD). It works by boosting...
by Sarah Martin | June 15, 2015 | Health Risk Solutions, Health Risk Solutions General, Pharmacy
Whether you’re a plan sponsor, doctor, patient or pharmacy benefit manager, you’re likely to be eagerly awaiting the release of new specialty medications to treat high cholesterol. Called PCSK9 inhibitors, these drugs are expected to hit the market for the first time...
by Sarah Martin | May 5, 2015 | Health Risk Solutions, Pharmacy
According to a recent story in the New York Times (Speedy Drug Approvals Have Become the Rule, Not the Exception), FDA approval timeframes for new specialty drugs are being shortened and the pipeline is filling up with new medications. That’s why it’s more important...
by Sarah Martin | February 20, 2015 | Health Risk Solutions, Pharmacy
A new class of injectable medications will soon be available for use in treating high cholesterol. These drugs are called PCSK9 inhibitors, and they’re currently still in development by a variety of pharmaceutical companies. Approvals are expected midyear. While news...
by Sarah Martin | October 7, 2014 | Health Risk Solutions, Pharmacy
Today Bristol-Myers Squibb announced their decision to pull out of the hepatitis C drug race. We were expecting to see a combination therapy from Bristol-Myers in December or early 2015. Gilead, the manufacturer of Sovaldi and another Sovaldi combination therapy...
